Immunothérapie : Libre accès
Libre accès

Abstrait

Radiomics Approaches to Assess Tumours Anti-PD-1 or Anti-PD-L1 Immunotherapy: Imaging Biomarkers, New Development and Challenges

Jinming Yu Yu

Although immunotherapy has changed the management of various tumors and obtained unexpected responses, lots of cancer patients failed in this new treatment. Thus, identifying predictive biomarkers to select patients who benefit from immune checkpoint blockades therapy is crucial. Computational medical imaging (called as radiomics), which is a rapidly evolving discipline, having the advantage of non-invasive ,the ability to further describe the phenotype of the tumor and evaluate its microenvironment. This review is focused on the progress of computational imaging analysis and radiomics-based biomarkers for evaluating efficacy of anti-PD-1/PD-L1 immunotherapy, and predicting immunerelated side effects.